Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization
- 1 February 2014
- journal article
- clinical trial
- Published by Elsevier in Clinical Biochemistry
- Vol. 47 (3) , 184-190
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular CarcinomaCardioVascular and Interventional Radiology, 2009
- Cancer Mortality in Italy, 2003Tumori Journal, 2009
- Single-Center Phase II Trial of Transarterial Chemoembolization With Drug-Eluting Beads for Patients With Unresectable Hepatocellular CarcinomaThe Cancer Journal, 2009
- Hepatocellular carcinomaThe Lancet, 2003
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Prognostic prediction and treatment strategy in hepatocellular carcinomaHepatology, 2002
- International trends and patterns of primary liver cancerInternational Journal of Cancer, 2001
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999